Hemimegalencephaly (HMG) is a developmental brain disorder characterized by an enlarged, malformed cerebral hemisphere, typically causing epilepsy that requires surgical resection. We studied resected HMG tissue to test whether the condition might reflect somatic mutations affecting genes critical to brain development. We found that two out of eight HMG samples showed trisomy of chromosome 1q, which encompasses many genes, including AKT3, a gene known to regulate brain size. A third case showed a known activating mutation in AKT3 (c.49G/A, creating p.E17K) that was not present in the patient's blood cells. Remarkably, the E17K mutation in AKT3 is exactly paralogous to E17K mutations in AKT1 and AKT2 recently discovered in somatic overgrowth syndromes. We show that AKT3 is the most abundant AKT paralog in the brain during neurogenesis and that phosphorylated AKT is abundant in cortical progenitor cells. Our data suggest that somatic mutations limited to the brain could represent an important cause of complex neurogenetic disease.
INTRODUCTION
The role of somatic mutation in human brain development and disease is a source of intense interest to developmental neuroscientists and human geneticists. Somatic mutation, such as by the mobilization of retrotransposons during neurogenesis (Muotri and Gage, 2006; Singer et al., 2010) or by copy number variation in neurons (Rehen et al., 2005) , has been proposed as a source of normal neuronal diversity. However, neurogenetic disease has also been attributed to somatic, postzygotic mutations in TSC2, NF1, and DCX that are detectable in some, but not all, blood cells and appear to be present in some, but not all, brain cells (Gleeson et al., 2000; Messiaen et al., 2011; Qin et al., 2010; Vogt et al., 2011) . On the other hand, it has been essentially impossible to study potential roles of mutations that are limited to brain cells, because such mutations are by definition absent from blood and other tissues typically available for genetic study. Such somatic mutations could conceivably play important roles in complex neurogenetic disorders, such as epilepsy, intellectual disability, and psychiatric disease, for which prominent roles for de novo mutations have been well documented (Awadalla et al., 2010; Poduri and Lowenstein, 2011; Ropers, 2008) . Here we describe a highly epileptic disorder, hemimegalencephaly (HMG, literally, enlargement of one brain hemisphere), as a model to characterize the role of somatic mutation in the developing brain.
HMG is a developmental brain disorder characterized by an enlarged, malformed cerebral hemisphere (Flores-Sarnat et al., 2003) . The clinical presentation typically includes intellectual disability and severe, intractable epilepsy, often necessitating surgical removal or disconnection of the abnormal hemisphere for seizure control (Gowda et al., 2010) . Although no specific genetic causes have been identified for isolated HMG, HMG has been reported in association with Proteus syndrome (Griffiths et al., 1994) -another multisystem overgrowth disorder that has recently been associated with somatic activating mutations in the gene AKT1 (Lindhurst et al., 2011) -as well as other rare neurocutaneous syndromes (Mochida et al., 2013) . There are also rare reports of HMG associated with tuberous sclerosis complex (TSC) (Cartwright et al., 2005) , a syndrome in which multiple organ systems display disordered and sometimes cancerous growths.
The striking asymmetry of the brain in individuals with HMG has long suggested that HMG reflects spontaneous, somatic, clonal mutation limited to the brain, analogous to cancer but without cellular transformation and ongoing proliferation. We hypothesized that the somatic mutations causing HMG might be essentially restricted to the brain and detectable by direct study of affected brain tissue. Here we show that three out of eight HMG samples studied showed somatic mutations involving AKT3: two with large duplications of chromosome 1q encompassing AKT3, as well as many other genes, and a third carrying a known activating mutation in AKT3. Moreover, we demonstrate that at least two out of three of these mutations are not detectable in blood of the same individuals, reflecting somatic mutations affecting the brain preferentially or exclusively.
RESULTS AND DISCUSSION
We studied eight samples of brain tissue resected at the time of epilepsy surgery and identified two that showed trisomy of chromosome 1q. The first partial trisomy case (HMG-1) was a nondysmorphic boy requiring hemispherectomy at 15 months of age for treatment of epilepsy due to HMG. He had no clinical evidence of nonnervous system involvement. Magnetic resonance imaging (MRI) showed left-sided HMG, with the extent of the lesion reflected in the large amount of brain removed in order to control his seizures ( Figures 1C and 1D show the left HMG before surgery, and Figures 1E and 1F show only the normal right hemisphere remaining after surgery). After surgery, seizures were dramatically reduced from approximately ten per day to one to four per month. At age 6, he had right-sided weakness but could walk independently; he had good language comprehension, though his speech production was limited to a few words, and he attended school with special services. Neuropathological analysis from the affected hemisphere revealed diffuse abnormalities of cortical development (cortical dysplasia) with irregular cortical architecture, ectopic bands of gray matter in the subcortical white matter, scattered proliferating cells, and abnormal neurons consistent with previous reports of HMG (Figure 2 ) (Flores-Sarnat et al., 2003) . Copy number evaluation of single nucleotide polymorphism (SNP) data showed increased signal for the entire q arm of chromosome 1 in the brain sample (Figures 3A and 3B and Figure S1 available online), with an estimated copy number of 2.41 (SD 0.12) . No other chromosomes displayed abnormal copy number ( Figure 3A ). Quantitative PCR (qPCR) confirmed the 1q trisomy, generating a calculated copy number of 2.39 (SD 0.30) from one brain sample; from a second sample, the calculated copy number was 2.68 (SD 0.16), 2.76 (SD 0.20), and 2.73 (SD 0.13) at 1q21.3, 1q31.1, and 1q42.2, respectively ( Figure 3C ). The intermediate copy number, between 2 and 3, suggests a mixture of normal and trisomic cells in the brain regions sampled, and together these results suggest that the ratio of normal and abnormal cells varied somewhat in different parts of the resected tissue. High-resolution karyotype and qPCR of peripheral blood cells in the patient did not reveal any evidence of trisomy 1q in these nonbrain cells ( Figure 3C and data not shown).
We identified a second case of partial gain of chromosome 1, again involving the entire 1q arm, based on SNP data from the brain sample of an individual (HMG-2) reported to have isolated HMG on MRI, similar but somewhat milder neuropathological findings of mild dysplasia (manifest primarily as a thickened cortical ribbon), and no other medical problems ( Figure S1 ). Copy number at 1q assessed by qPCR was 2.75 (SD 0.28), again consistent with mosaic partial trisomy. Leukocytes or other tissues were not available from this individual, so the somatic nature of the mutation could not be directly tested. Inspection of the published literature and the Database of Genomic Variants (http://projects.tcag.ca/variation), a large database of copy number variation, suggests that there are no known control individuals with large constitutional duplications of 1q (Iafrate et al., 2004) . Wintle et al. (2011) recently conducted a sensitive copy number analysis on brain tissue from 52 individuals without HMG and reported no duplications of chromosome 1q larger than 1 Mb (whereas the 1q region spans nearly 250 Mb), demonstrating that our finding of two out of eight cases with trisomy of 1q is not a common variant.
Chromosome 1q contains many genes, but among them AKT3 is a particularly strong candidate for HMG, because deletions including AKT3 are associated with microcephaly, suggesting a role for AKT3 in control of brain size (Ballif et al., 2012; Boland et al., 2007; Hill et al., 2007) . Furthermore, somatic-activating mutations in AKT1 cause Proteus syndrome, and somatic-activating mutations in AKT2 have been reported to cause hypoglycemia and asymmetrical somatic growth (Hussain et al., 2011; Lindhurst et al., 2011) . Earlier screening for candidate mutations in cancer-associated genes did not reveal any mutations in our cases (data not shown), but AKT3 was not included among the genes screened. We sequenced AKT3 as a candidate gene in the six remaining nontrisomy cases of HMG and identified one out of six with a somatic point mutation in AKT3. This case (HMG-3) was a nondysmorphic boy requiring hemispherectomy at 5 months of age for seizures beginning in the first week of life due to right-sided HMG (MRI before surgery is shown in Figures  1G and 1H and after surgery in Figures 1I and 1J ). After surgery, he had two periods of breakthrough seizures but has been seizure free for 6 years at 9 years of age. He has left-sided weakness but walks independently, speaks fluently, is able to read, and attends school with special education services. DNA sequencing revealed the mutation AKT3 c.49G/A, p.E17K in the DNA derived from the brain; this mutation was not detectable in DNA derived from the patient's leukocytes ( Figure 3D ). To confirm the presence of the mutation in brain cells, we cloned the PCR product from the brain and resequenced multiple clones ( Figure 3D ). Forty-six individual clones showed either the mutant sequence only (8/46, or 17.4%) or the normal sequence only (38/46, or 82.6%) (examples are shown in Figure 3D) , suggesting that the mutation exists in the heterozygous state in z35% of the cells.
The activating nature of the AKT3 E17K mutation has been shown previously biochemically (Davies et al., 2008) . Evaluation of data from the Exome Variant Server revealed that the AKT3 c.49G/A point mutation is not present in >5,000 control individuals (http://evs.gs.washington.edu). Published estimates suggest a somatic mutation frequency on the order of 10 À9 per cell division (Lynch, 2010b) ; published mutation rates from exome sequencing in humans, coupled with extrapolation of somatic mutation rates in mouse, suggest a <1 3 10 À7 chance that the specific AKT3 c.49G/A mutation would occur by chance (Awadalla et al., 2010; Lynch, 2010a) . Somatic mutations in AKT3, which encodes the serine-threonine kinase protein kinase B-gamma, have been reported in cancers, including a p.G171R substitution mutation in a glioma (Bamford et al., 2004) . The AKT3 c.49G/A E17K mutation itself has been observed in melanoma and lung cancer, and melanoma cell lines overexpressing this exact missense mutation have been demonstrated to show increased AKT phosphorylation (Davies et al., 2008; Do et al., 2010) . Most remarkably though, the somatic AKT3 mutation we report is precisely paralogous to the recurrent E17K mutations in AKT1 associated with Proteus syndrome and recurrent E17K mutations in AKT2 associated with hypoglycemia and left-sided overgrowth, each also with varying degrees of mosaicism (Hussain et al., 2011; Lindhurst et al., 2011) . Interestingly, despite prior reports of Proteus-associated HMG (Griffiths et al., 1994) , no brain malformations are reported in the patients with AKT1 and AKT2 mutations, consistent with the observation in mice that AKT3 may be the predominant functional member of the AKT family in the human brain (Easton et al., 2005) .
AKT3 expression in the human fetal brain is higher than AKT3 expression in any other tissue sampled (Wu et al., 2009 ), suggesting that its primary role is in brain development. In contrast, AKT1 and AKT2 show levels of fetal brain expression comparable to or lower than those seen in other tissues (Wu et al., 2009) . We compared the expression levels of AKT1, AKT2, and AKT3 by RNaseq analysis of the perisylvian cortex of the human brain at 9 weeks' gestation, during active neurogenesis, and found that AKT3 is expressed at higher levels than AKT1 and AKT2 (normalized read depth, reads per kilobase-exon per million mapped reads: AKT1 = 51.90, AKT2 = 18.50, AKT3 = 90.52). Examination of published data sets reveals that AKT3 is expressed at a higher level than AKT1, and both are expressed at higher levels than AKT2, starting at 8 weeks and for the duration of human embryonic cortical development (Kang et al., 2011) . To determine the cell types in the brain that would likely be affected by activation of AKT3, we performed immunohistochemistry in sections of mouse brain by using an antiserum that recognizes all three phosphorylated forms of AKT (P-Akt). We observed widespread P-Akt localization in the developing cortex, with notable enrichment in apical progenitor cells in the ventricular zone. For example, a subset of cells marked by P-Akt also showed the presence of P-Vimentin 4A4, illustrating the presence of Akt activity in dividing radial glial cells (Figure 4 ). Similarly, P-Akt colocalized with phosphoHistone H3, a marker of M phase, in dividing apical progenitors as well as GLAST, a marker of radial glial cells (data not shown). Because these apical progenitor cells give rise to both neurons and glia, this localization is consistent with activation of AKT3 in both neurons and glia. Abnormal AKT function would be consistent with the MRI patterns and neuropathological studies (Figures 1 and 2) , which show abnormal organization of neurons in the cortex and abnormal MRI signal characteristics of white matter.
Our data suggest that activation of AKT3, either by duplication or by point mutation, contributes to hemispheric brain overgrowth. Two of our cases (the point mutation and one partial trisomy) are confirmed to be de novo, somatic mutations, undetectable in blood, and although nonbrain tissues were not available from the other partial trisomy case, this is likely to be a somatic mutation as well, because individuals reported with constitutional trisomy 1q, even a portion of 1q, show dysmorphic features and, in nearly all cases, early lethality (Mark et al., 2005; Mefford et al., 2008; Patel et al., 2009) . We postulate that increasing AKT3 dosage and activation of AKT3 would have the same effect in the setting of a somatic mutation. Interestingly, HMG has not been reported in the constitutional trisomy cases, even those that have partial trisomy including AKT3. It is possible that HMG might not be present in the cases with early lethality; perhaps more important, because all of the constitutional trisomy 1q cases were de novo, the trisomy may not be present in all tissues. Though we have not sampled other tissues, there was no clinical evidence of extracerebral involvement phenotypically in any of the three cases, suggesting that either the mutation was limited to the brain or activation of AKT3 in other tissues does not have phenotypic consequences. Increased rates of brain cancer are not reported in the setting of isolated HMG. In the cases we report here, which have not shown any form of cancer, it is likely that activation of AKT3 disrupts normal cortical development but does not result in continued dysregulated growth outside the setting of cortical progenitor cells.
Further support for the role of AKT3 in controlling brain size comes from animal studies. A mouse Akt3 knockout model shows selective reduction in brain size due to decreased neuronal number and size (Easton et al., 2005) , whereas mice with an activating mutation in the kinase domain of Akt3 show larger hippocampal size and abnormal Ki67-positive ectopic neurons in the hippocampus (Tokuda et al., 2011) . Additionally, in zebrafish, overexpression of wild-type akt3 produces increased embryonic brain thickness (Chen et al., 2011) . All of these results strongly suggest that AKT3 activity dynamically regulates brain size and that increased dosage of AKT3 might increase brain size in humans.
Somatic mosaicism refers to the presence of more than one genetically distinct population of cells in an individual. Somatic mutations are thought to arise not infrequently during development (Youssoufian and Pyeritz, 2002) , and some chromosomal rearrangements and mutations that may be lethal if present in the entire embryo could be sustained in clonal populations of cells and produce localized abnormalities. The size and architecture of HMG may be determined in part by the stage at which the mutation occurs relative to the period of neurogenesis, which is when AKT3 normally becomes the predominant AKT form in brain. As better techniques emerge for copy number and whole-exome or genome sequencing on smaller and smaller amounts of DNA, somatic mutations in other genes might emerge as causes of other neurogenetic disorders not associated with obvious morphological phenotypes like HMG. For example, de novo copy number variations are an important cause of autism spectrum disorders and schizophrenia (Sanders et al., 2011) , and hence may also occur somatically. In epilepsy, at least one third of individuals with imaging-negative, refractory, focal seizures show pathological evidence of dysplasia (Porter et al., 2003) that may also be due to somatic mutations. Therefore, more detailed exploration of somatic mosaicism may allow for better genetic understanding of many neurogenetic disorders, especially those for which de novo mutations are known to play a role. 
Phenotypic Assessment
Detailed clinical information and leukocyte-derived DNA were available for six cases enrolled in human subjects research, including HMG-1 and HMG-3. We reviewed the history and examination of each case reported (A.P., B.F.D.B., and J.J.R.) and the MRI (A.P., A.J.B., and C.A.W.). Table S1 summarizes the imaging and neuropathological findings of the three cases with mutations.
Neuropathological Analysis
Formalin-fixed paraffin-embedded sections from the clinical resection specimens were obtained from the CHB pathology archives for pathological rereview by a board-certified neuropathologist (K.L.L.). Slides were stained with hematoxylin and eosin (H&E) and cresyl violet and luxol fast blue according to standard methods.
Immunohistochemistry was performed by using phosphorylated neurofilament (SMI31, Covance) and Ki67 (DAKO, Clone MIB1) using DAKO Envision Plus and diaminobenzidine development.
Copy Number Assessment
We obtained eight samples of flash-frozen brain tissue resected during focal epilepsy surgery for HMG. DNA was extracted by using standard methods and was then digested, amplified, and hybridized to Affymetrix 100K SNP arrays for six of the samples (Affymetrix). In the original arrays (e.g., 100K), copy number was assessed based on intensity of signal from each SNP. For the Affymetrix 6.0 arrays, copy number probes are included in addition to the full array of SNPs, and both are used for quantitation. The Gaussiansmoothed signal log2-ratio of all probe intensities normalized to a reference of 270 normal HapMap samples was calculated by Affymetrix Genotyping Console with standard settings. Additional DNA from HMG-1 and two other samples was assessed by using the Affymetrix 6.0 SNP array. The software dChipSNP was used for analysis.
For HMG-1 and HMG-2, we performed qPCR in cases in which copy number change was detected. Primers were designed to 1q44 and 1p21.1. DNA from two control individuals (Promega) was used for comparison. We repeated qPCR in an additional specimen from HMG-1 for confirmation by using primers targeting 1p (1p13.3, 1p32.3, and 1p36.2) and 1q (1q21.3, 1q31.1, and 1q42.2).
Leukocytes were obtained from six of the cases; DNA was extracted by using standard methods and was used for SNP analysis as above. For HMG-1, we performed SNP analysis and clinical karyotype to assess for the presence of the trisomy 1q in peripheral blood leukocytes (evaluating 50 cells to detect even a low level of mosaicism).
Screening for Candidate Mutations in Oncogenes
Based on the hypothesis that our cases harbor somatic mutations in genes that result in dysregulated growth, we screened the DNA from the brain samples for a panel of known point mutations in cancer-associated genes (OncoMap Project, Dana Farber Cancer Institute) (MacConaill et al., 2009 ). This panel did not include AKT3; genes included in the 1q region were ABL2, DDR2, and NTRK1.
Evaluation for AKT3 c.49G/A-Activating Mutations
We designed primers by using Primer 3 software (http://primer3.sourceforge. net) for the second exon of AKT1, AKT2, and AKT3 in order to evaluate nucleotide position 49. In cases without trisomy 1q, we sequenced DNA from brain tissue (six HMG cases) and leukocytes from the same cases (five cases).
Evaluation for Mosaicism of the AKT3 Mutation in HMG-3
To determine the degree of mosaicism in the brain tissue specimen of HMG-3, we performed TOPO TA cloning by using standard methods (Invitrogen), successfully analyzing 46 clones for the AKT3 c.49G/A mutation.
Estimation of the Likelihood that the AKT3 Mutation Would Occur by Chance Published sequencing data indicate that each individual has approximately one to two de novo nonsynonymous variants per diploid genome generation (Awadalla et al., 2010) . The likelihood that this would affect this one base pair in all of the 6 3 10 7 base pairs of the diploid genome is therefore 23 10 À8 -3 3 10 À8 . Correcting by a factor of 10 to reflect the increased somatic versus germline mutation rate (Lynch, 2010a) and accounting for three potential mutations at a given nucleotide position, the estimated likelihood that our mutation would occur by chance is at most 1 3 10 À7 .
Localization of P-AKT in the Developing Cortex
We labeled embryonic mouse cortex at embryonic day 10.5 (E10.5), E12.5, E14.5, E16.5, and E18.5 with the following antibodies: rabbit anti-phosphoAkt 1:50 (4060S, Cell Signaling), mouse anti-phospho-Vimentin 4A4 1:100 (Assay Designs), rabbit anti-phospho-Histone H3 1:400 (Upstate), and anti-GLAST 1:5,000 (Chemicon).
RNA-Seq Analysis of AKT Isoforms in the Developing Human Cortex
We obtained snap-frozen brain tissue from a human fetus at roughly 9 weeks' gestation from the Institute of Human Genetics at Newcastle University. RNA was isolated from several regions of the cortex, including the perisylvian region, and purified by using standard methods. We purified polyA-tailed mRNA by using an Oligotex mRNA minikit (QIAGEN) and prepared a barcoded sequencing library by using the SOLiD Whole Transcriptome Analysis Kit (Applied Biosystems). We sequenced the library on the SOLiD v3 Plus system (read depth: 105 million reads), mapped the reads with Bioscope v1.2 (Applied Biosystems) to the hg18 human genome reference, and normalized coverage of uniquely mapping reads to the number of million mapped reads.
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